Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells

Figure 2

Expression of differentiation markers before and after formation of embryoid bodies from lovastatin treated or untreated cells. (a) Expression of the differentiation markers SOX1, OTX2 (ectodermal lineage), brachyury, HAND1 (mesodermal lineage), and SOX17 (endodermal lineage), and the pluripotency marker OCT4 in hES cells as detected by flow cytometric assay. Embryoid bodies were formed from untreated or 20 μM lovastatin treated hES cells and single cell suspension was used to ascertain the expression of the differentiation markers. (b) Expression of differentiation markers for untreated and lovastatin (L) treated hES cells and (c) of formed embryoid bodies. Results are shown as mean ± SEM (). (d) Morphology of formed EB (on day 5) from untreated and lovastatin treated hES cells.

(a)

(b)

(c)

(d)